BeiGene, Ltd., a clinical-stage biopharmaceutical company, announced the dosing of the first patient in a Phase I clinical trial of BGB-A317, an anti-PD-1 monoclonal antibody, in mainland Chinese patients with advanced solid tumors. This trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-A317.
John V. Oyler, Founder, CEO, and Chairman of BeiGene, expressed enthusiasm about the therapeutic potential of BGB-A317, highlighting promising data from an ongoing Phase I study in Australia, New Zealand, the United States, and Taiwan. The study was recently presented at the 2016 Society for Immunotherapy of Cancer Annual Meeting.
The Phase I open-label, multi-center study is led by Professor Yilong Wu from Guangdong General Hospital, with co-lead investigators Professor Lin Shen and Professor Jun Guo from Beijing Cancer Hospital. BGB-A317 is an investigational humanized monoclonal antibody designed to bind to PD-1, a cell surface receptor crucial for downregulating the immune system by preventing T-cell activation. It is being developed as a monotherapy and in combination with other therapies for various cancers.
BeiGene, with over 300 scientists, clinicians, and staff across mainland China, the United States, Australia, and Taiwan, is focused on developing molecularly targeted and immuno-oncology cancer therapeutics. The company is committed to creating combination solutions that aim to have a meaningful and lasting impact on cancer patients.
This press release contains forward-looking statements regarding the clinical data of BGB-A317, its potential implications for future development, and BeiGene's anticipated clinical development and regulatory milestones. Actual results may differ due to various factors, including the efficacy and safety of drug candidates, clinical results, regulatory actions, market acceptance, intellectual property protection, reliance on third parties, operating history, and funding availability.
